Sunday, April 20, 2025 2:23 am


MCQs on liver part- 2

This session covers 10 exam productive MCQs on LIVER for the preparation of MBBS, INI-CET, NEET PG, INI-SS, FMGE,MS,DNB entrance and UPSC Combined Medical Services examinations.
For ANSWERS AND DESCRIPTION please watch the following YouTube video:

https://youtu.be/3ZfdmM94T7g

A. Hepatocellular carcinoma.

B. Hepatoblastoma.

C. Haemangioendothelioma.

D. Intrahepatic cystadenocarcinoma.

A. may be associated with autosomal dominant polycystic disease of kidney.
B. rarely symptomatic.
C. ultrasound is the investigation of choice.

D. liver transplantation is the treatment of choice.

A. Adenoma.

B. Hepatoma.

C. Cavernous haemangioma.

D. Lipoma.

A. Diuretic therapy.

B. Large-volume paracentesis.

C. Liver transplantation.

D. Salt restriction and fluid restriction.

E. Transjugular intrahepatic portosystemic shunt (TIPS).

A. Change his immunosuppression to a calcineurin-inhibitor-containing regimen now that he is 9 months post-transplant.

B. Surveillance for HCC with an abdominal ultrasound every 6 months for the next two years.

C. Adjuvant systemic therapy with atezolizumab plus bevacizumab for five years post-transplant.

D. CT abdomen/pelvis and serum alpha-fetoprotein (AFP) every 6 months for the next two years.

A. Administer diuretics and beta-blockers.
B. Administer intravenous albumin in combination with terlipressin.
C. Recommend haemodialysis.
D. Recommend liver transplantation.

E. Recommend transjugular intrahepatic portosystemic shunt (TIPS).

A. MELD score.
B. PELD score.
C. Child-Turcotte -Pugh score.

D. SOFA Score.

A. Associated with a more severe disease course.
B. Present in non-hepatic autoimmune disorders.
C. Target of anti-SLA is tRNP(Ser)Sec.

D. Specific serologic marker for autoimmune liver diseases.

A. Liver resection is never done.
B. Laparoscopic de-roofing of cyst is performed.
C. Mostly asymptomatic.

E. Most common causative organism is Echinococcus Granulosus.

A. FNH
B. Haemangioma
C. Hepatic metastasis

D. HCC


Leave a Reply

Your email address will not be published. Required fields are marked *

Verified by MonsterInsights